^
Association details:
| Biomarker: | NRAS wild-type |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Colon Cancer...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE - CHEMOTHERAPY REGIMENS...FOLFIRI + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)...Irinotecan + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFOX + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFIRINOX or mFOLFIRINOX + panitumumab (KRAS/NRAS/BRAF WT and left-sided tumors only)
Secondary therapy:
FOLFIRI; irinotecan; FOLFOX; FOLFIRINOX
Source:
Title:
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Excerpt:
...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
Trial ID:
Source:
Title:
MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
Excerpt:
...RAS (KRAS exons 2,3 and 4; NRAS exons 2 and 3) wild type as assessed by the investigator's choice of testing laboratory....
Trial ID:
More C2 evidence
Source:
Title:
FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.
Excerpt:
...Histologically proven diagnosis of colorectal cancer.Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.At least one measurable lesion according to RECIST1.1Availability of a tissue tumour sample (primary tumour and/or metastatic sites)Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.RAS (codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS genes) and BRAF (V600E mutation) wild type status of primary colorectal cancer or related metastasis (local or central laboratory assessment). ...
Trial ID:
